Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Sanofi SA is a French multinational pharmaceutical and healthcare company headquartered in Paris, renowned for its research, development, manufacturing, and marketing of innovative medicines and vaccines. Established in 1973, it has evolved through key mergers, including with Synthélabo in 1999 and Aventis in 2004, forming a global leader with over 90,000 employees across 90 countries. Sanofi focuses on seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines, positioning it as the world's largest vaccine producer via its Sanofi Pasteur subsidiary. Its portfolio spans prescription drugs like Dupixent for eczema and autoimmune conditions, Lovenox for thrombosis, Taxotere for cancer, and treatments for rare diseases such as Gaucher's and hemophilia. Sanofi also offers over-the-counter products including Allegra and IcyHot. As an R&D-driven, AI-powered biopharma entity, it invests heavily in immunology, neurology, diabetes innovation, and mRNA technologies, maintaining a robust pipeline of 80 compounds in clinical development across five therapeutic areas to address unmet medical needs and advance public health worldwide.
€75.07
+€1.31 (+1.78%)
EOD Jun 26, 2026 · Twelve Data
20.54% operating margin is above average. ROIC at 8.49%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue grew 5.5%, steady but not accelerating.
Even for strong businesses, today's 12x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
12.2x earnings, 13.3x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€47.35B
▲ +5.5% YoY
Net Income (TTM)
€7.58B
▲ +39.7% YoY
Op. Margin
19.84%
▼ -0.8pp YoY
ROIC
8.49%
▲ +0.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€6.80B
▲ +22.5% YoY
Op. Cash Flow (TTM)
€6.80B
▲ +33.4% YoY
Net Debt
€11.86B
Cash & Equiv.
€8.47B
3Y CAGR: +1.0%
3Y CAGR: -4.7%
Continue Research
At a P/E of 12.2 and a price-to-free-cash-flow of 13.3, Sanofi (SAN.XPAR) trades around a two-stage DCF intrinsic value of about €88.04 per share, so at €75.07 the stock looks around fair value (17.3% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Sanofi scores 41/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 5.3%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €88.04 per share for SAN.XPAR, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €66.03. At today's €75.07, that puts the stock about 17.3% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Sanofi scores 41 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 19.8% operating margin and a 8.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Sanofi pays a regular dividend of about €3.96 per share per year (typically in quarterly installments), a yield of roughly 5.3% at the current price. That is a payout ratio of about 63.0% of earnings, so the dividend is well covered. Sanofi has grown the dividend at roughly 4.5% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For SAN.XPAR's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. SAN.XPAR currently trades around its estimated intrinsic value and scores 41/100 on quality (mixed). It also yields about 5.3%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.